**Request to produce transgenics**

[ ]  I agree to adhere to the CTC Fair Publication Policy (<https://www.ed.ac.uk/bioresearch-veterinary-services/transgenics/about>).

Please supply all requested information in full using a new form for each construct.

**Part A: Contact details**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project leader:** |  | **e-mail:** |  |
| **Lab contact:** |  | **e-mail:** |  |
| **Project leader department/UoE location:** |  |
| **Charge to (Tick@lab project code):** |  |

**Part B: Details of line to be established**

|  |  |
| --- | --- |
| **Name of line:** |  |
| **Please select the type of service required:** | [ ]  IVF (fresh sperm)[ ]  IVF (frozen sperm)[ ]  TAT-CRE embryo treatment[ ]  ICSI [ ]  Embryo rederivation (fresh embryos)[ ]  Embryo rederivation (frozen embryos)[ ]  ES cell injection[ ]  Microinjection CRISPR/Cas9 (pronuclear)[ ]  Microinjection CRISPR/Cas9 (cytoplasmic)[ ]  Microinjection Transgene (pronuclear)[ ]  Electroporation |
| **Strain of embryo donor:** | **Mouse:**[ ]  C57BL/6J (Charles River)[ ]  C57BL/6JOlaHsd[ ]  C57BL/6NCrl[ ]  B6CBAF1/Crl[ ]  Crl:CD1(ICR)[ ]  Hsd:ICR (CD-1)[ ]  BALB/cAnNCrl[ ]  BALB/cAnNHsd[ ]  BALB/cOlaHsd[ ]  FVB/NCrl[ ]  FVB/NHanHsd[ ]  other:**Rat:**[ ]  Sprague Dawley (Hsd:SD)[ ]  CD IGS (Crl:CD(SD))[ ]  Crl:LE[ ]  other: |
| **Place of permanent housing:** | [ ]  ASH[ ]  CRM[ ]  GSQ[ ]  HRB[ ]  IRR[ ]  LFR[ ]  MAR[ ]  ROS[ ]  WGH[ ]  other: |
| **For rederivations (IVF/embryos/ICSI) only:** |
| **Cryo/Import #:** |  |
| **Expected genotype(s) of rederived pups:** |  |

**Part C: Tick@lab information**

|  |  |
| --- | --- |
| **Genetic background:** | **Mouse:**[ ]  C57BL/6J (Charles River)[ ]  C57BL/6JOla[ ]  C57BL/6NCrl[ ]  B6CBAF1 (Crl)[ ]  CD-1 IGS (Crl:CD1(ICR))[ ]  CD-1 (Hsd:ICR(CD-1))[ ]  BALB/cAnNCrl[ ]  BALB/cAnNHsd[ ]  BALB/cOlaHsd[ ]  FVB/NCrl[ ]  FVB/NHanHsd[ ]  mixed[ ]  other:**Rat:**[ ]  Hsd:SD[ ]  Crl:CD(SD)[ ]  Crl:LE[ ]  other: |
| **Traits/genetic modification** (short description of changes made to this transgenic/mutant line in plain text): |  |
| **Technical scientific name** (e.g. B6.129P2-Apoa1tm1Unc/J); please refer to https://www.informatics.jax.org |  |
| **Originating establishment/Source:** |  |
| **Citation/PubMed ID** (if available): |  |
| **Name of the RESPONSIBLE PERSON in the team the line should be assigned to:** |  |
| **Genotyping information** (list a locus name and all possible genotyping outcomes for each allele; e.g. Apoa1 = wt, het, hom; Brd2 = WT, WT/GA, GA/GA; CMV-Cre = pos, neg; Nestin-Cre = wt, tg): |  |
| **Numbering scheme:** | [ ]  linear series[ ]  X-Y.Z (X = animal ID, Y = Mating, Z = Litter)[ ]  alternate (sex)[ ]  other: |
| **Name of the TEAM the line should be assigned to:** |  |

**Part D: Genotyping information – for rederivations only**

As part of the rederivation service (IVF, embryo rederivation), animals born will be genotyped using Transnetyx. This is currently not available for transgenic production services (microinjection, ES cell injection, electroporation).

A genotyping assay has been set up with Transnetyx:

[ ]  yes: please share your strain with trantec@ed.ac.uk

[ ]  no

If no assay has been set up yet, CTC can liaise with Transnetyx to design an assay. Please supply any information relevant such as:

* MGI number (if available):
* Detailed description of the allele/how the allele was constructed:
* PCR primers and band size:
* Construct map, sequencing data:

Once GA animals have been confirmed, 2 animals (if available one male, one female) will be chosen for genetic monitoring using Transnetyx’ MiniMUGA platform (https://www.transnetyx.com/monitoring).

**Part E: PPL information**

Which PPL will be used for subsequent use of these animals?

[ ]  please provide PPL number and name of PPL holder:

[ ]  they will be bred/maintained on the transgenic license held by Dr. Sharp

**Part F: PPL authorisation**

As a condition attached to the PPL under which CTC operates, we are obliged to get outline permission in advance for all new transgenic and knockout strains created or imported. Please complete the following pages, giving some brief details as to the nature and purpose of the proposed strain. This information will be assessed by a local committee. Please complete this part with as much information as possible.

As the outline of this part is the same as in a GA appendix file, you can copy/paste from a previous GA appendix if you are re-deriving an already existing line. If you are creating a new line, this information here will be used to create the GA appendix in Tick@lab.

Please review your GA appendix once your line has been established, and update on phenotypes or adverse effects, as an up-to-date GA appendix is a mandatory requirement for the Home Office.

Once approval has been gained, your job will be assigned a number and a transgenic team to fulfil the job.

|  |
| --- |
| **Background: Please give details about the specific genetic alteration/mutation and how the gene of interest fits with the scientific aims:** |
|  |
| **Objectives: Please provide information about how this strain will be used to achieve the scientific objectives outlined in the relevant PPL/programme of work and what potential benefits might derive from this work:** |
|  |
| **Phenotypes/adverse effects: List all (predicted) phenotypes, including adverse effects and observable traits/abnormalities that have potential welfare implications, together with welfare assessment advice (if appropriate) and a time scale of when these effects can be observed. Examples include developmental and behavioural defects; physical abnormalities; homozygous lethality, or incidence of unexpected death and immune status (if immunocompromised, or susceptible to specific parasites, bacteria etc.):** |
|  |
| ***For CRISPR projects only*: Phenotypes/adverse effects of non-desired mutations in founders: As above, but for non-desired CRISPR mediated mutations, e.g. indels rather than KI, homozygous targeting.** |
|  |
| **Care/Remedial Actions Required: List any additional care/husbandry requirements that are required for this line:** |
|  |
| **Prospective severity limit of breeding & maintenance protocol for new line with desired genotype:** | [ ]  Mild[ ]  Moderate[ ]  Severe |
| ***For CRISPR projects only*: Prospective severity limit of breeding & maintenance protocol for founders (keeping in mind possibility of non-desired mutations):** | [ ]  Mild[ ]  Moderate[ ]  Severe |

**For CTC internal use only**

|  |  |
| --- | --- |
| **Date form received:** |  |
| **TR number assigned:** |  |
| **PPL approval date:** |  |
| **NVS approval date:** |  |
| **TG unit assigned:** |  |